Novel Mucoadhesive Extended Release Tablets for Treatment of Oral Candidosis: “In Vivo” Evaluation of the Biopharmaceutical Performance

Llabot, Juan Manuel; Manzo, Rubén H.; Allemandi, Daniel Alberto

doi:10.1002/jps.21513

Cited by 10 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In volunteers, a sustained release of VA over the duration of wearing took place, with a comparable intervolunteer variability in saliva concentrations to other local drug delivery systems ( 36 , 41 ). In addition, we found this variability to be relatively random.…”

Section: Discussionmentioning

confidence: 81%

3D printing of a wearable personalized oral delivery device: A first-in-human study

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 81%

3D printing of a wearable personalized oral delivery device: A first-in-human study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Evaluating mucoadhesive tablets of nystatin in healthy volunteers, Llabot et al (2009) found that the tablets resided in the mucosa of the patients for 4.5 hours. During this period, the concentration of nystatin in the saliva remained higher than the MIC of the drug, according to the behavior observed in vitro [67].…”

Section: Resultsmentioning

confidence: 95%

Tablet of Ximenia Americana L. Developed from Mucoadhesive Polymers for Future Use in Oral Treatment of Fungal Infections

et al. 2019

View full text Add to dashboard Cite

The use of biocompatible polymers such as Hydroxypropylmethylcellulose (HPMC), Hydroxyethylcellulose (HEC), Carboxymethylcellulose (CMC), and Carbopol in solid formulations results in mucoadhesive systems capable of promoting the prolonged and localized release of Active Pharmaceutical Ingredients (APIs). This strategy represents a technological innovation that can be applied to improving the treatment of oral infections, such as oral candidiasis. Therefore, the aim of this study was to develop a tablet of Ximenia americana L. from mucoadhesive polymers for use in the treatment of oral candidiasis. An X. americana extract (MIC of 125 μg·mL−1) was obtained by turbolysis at 50% of ethanol, a level that demonstrated activity against Candida albicans. Differential Thermal Analysis and Fourier Transform Infrared Spectroscopy techniques allowed the choice of HPMC as a mucoadhesive agent, besides polyvinylpyrrolidone, magnesium stearate, and mannitol to integrate the formulation of X. americana. These excipients were granulated with an ethanolic solution 70% v/v at PVP 5%, and a mucoadhesive tablet was obtained by compression. Finally, mucoadhesive strength was evaluated, and the results demonstrated good mucoadhesive forces in mucin disk and pig buccal mucosa. Therefore, the study allowed a new alternative to be developed for the treatment of buccal candidiasis, one which overcomes the inconveniences of common treatments, costs little, and facilitates patients’ adhesion.

show abstract

“…This receptor medium allows keeping sink conditions in whole experiment. In this way the released nys would be soluble at the receptor medium, in contrast to other investigation, [26][27][28][29] which used water as release medium, in which nys is practically insoluble. 30 The system was kept at 32 ± 0.5°C, to mimic in vivo skin conditions and stirred continuously.…”

Section: Nanoemulsion Release Studymentioning

confidence: 96%

Evaluation of novel nystatin nanoemulsion for skin candidosis infections

Fernández-Campos

Naveros

Serrano

et al. 2012

Mycoses

View full text Add to dashboard Cite

One of the most common fungal skin infections is candidosis. Topical application of drugs at the pathological sites offers potential advantage of direct drug delivery to the site of action. The main aim of this work was to evaluate an optimal nystatin nanoemulsion for topical application avoiding undesirable side effects as systemic absorption and toxicity. Surface morphology and droplet size distribution of nystatin nanoemulsion was determined by transmission electronic microscopy and dynamic light scattering. Vertical diffusion Franz-type cells and high-performance liquid chromatography were used to perform the in vitro release and ex vivo human skin permeation studies. Transdermal permeation parameters were estimated from the permeation values using different theoretical approaches. Microbiological studies were performed to evaluate the antifungal effect. Nanoemulsion exhibited a spherical shape with smooth surface and mean droplet size between 70 and 80 nm. The pharmacokinetic release showed the nanoemulsion is faster than commercial ointment Mycostatin(®) improving the potential therapeutic index. Permeation studies demonstrated nystatin was not absorbed into systemic circulation and the retained amount in the skin was sufficient to ensure an antifungal effect. This antifungal effect was higher for nystatin loaded nanoemulsion than nystatin itself. A therapeutic improvement of the nystatin nanoemulsion treatment compared with the classical ones was achieved.

show abstract

Novel Mucoadhesive Extended Release Tablets for Treatment of Oral Candidosis: “In Vivo” Evaluation of the Biopharmaceutical Performance

Cited by 10 publications

References 22 publications

3D printing of a wearable personalized oral delivery device: A first-in-human study

3D printing of a wearable personalized oral delivery device: A first-in-human study

Tablet of Ximenia Americana L. Developed from Mucoadhesive Polymers for Future Use in Oral Treatment of Fungal Infections

Evaluation of novel nystatin nanoemulsion for skin candidosis infections

Contact Info

Product

Resources

About